

## Research Thesis

## Correlation between Vitamin D and Interleukin - 21 in Patients with Vitiligo

Amin Amer<sup>1\*</sup>, Mohamed Amer<sup>1</sup>, Elsayed Mohamed Galal Khater<sup>1</sup>, Ayman, Mohamed Marei<sup>1</sup> and Bashir Abdulalam A Firjani<sup>2</sup>

<sup>1</sup>Department of Dermatology and Venereology, Zagazig University, Egypt

<sup>2</sup>Department of Dermatology and Venereology, Tripoli, Libya

### Abstract

**Introduction:** Vitiligo is an acquired skin disease characterized by loss of functional melanocytes from the epidermis. Despite the several factors studied the pathogenesis of vitiligo remains unclear. Vitiligo could be associated with low vitamin D levels and high level of interleukin-21.

**Objective:** The aim of this study was to evaluate serum 25(OH) D levels, interleukin-21 serum levels and correlation between them in vitiligo patients in comparison of normal controls.

**Patients and Methods:** After meeting inclusion and exclusion criteria, serum 25 hydroxy vitamin D and interleukin-21 levels were assayed, in all subjects included in this case control study (21 patients and 21 age and sex matched healthy individuals).

Vitiligo disease activity index (VIDA), affected body surface area (BSA), site of lesion, age of patients and duration of vitiligo were evaluated in relation to vitamin D and interleukin-21 level.

**Results:** A total of 42 participants were enrolled in our study, 21 patients with vitiligo and 21 who served as controls. The mean serum level of vitamin D were significantly decreased in the patients group as compared with the control group (17.3ng/ml  $\pm$  5.3 vs 25.8 ng/ml  $\pm$  7.9,  $P < 0.05$ ). There was non-significant correlation between vitamin D level with age, duration of vitiligo, and affected body surface area ( $P > 0.05$ ), but there was significant difference in 25(OH)D levels between different grades of VIDA.

\*Corresponding author: Amin Amer, Department of Dermatology and Venereology, Zagazig University, Egypt, Tel: +20 1000040040; E-mail: aminamer74@gmail.com

**Citation:** Amer A, Amer M, Khater EMG, Marei AM, Firjani BAA (2019) Correlation between Vitamin D and Interleukin- 21 in Patients with Vitiligo. J Clin Dermatol Ther 5: 039.

**Received:** September 30, 2019; **Accepted:** November 08, 2019; **Published:** November 15, 2019

**Copyright:** © 2019 Amer AAM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

The mean serum level of interleukin-21 were significantly increased in the patients group as compared with the control group (606.1ng/ L  $\pm$  549.1 vs 137.5ng/ L  $\pm$  182). There was non-significant correlation between interleukin-21 level with age, duration of vitiligo, & affected body surface area ( $P > 0.05$ ), but there was significant difference in interleukin-21 levels between different grades of VIDA (increase disease activity associated with higher interleukin-21 level).

**Conclusion:** In this study, we found a significant 25(OH)D deficiency and significant high level of interleukin-21 in patients with vitiligo, suggesting that vitamin D deficiency and high-level interleukin -21 may play a role in the pathogenesis of vitiligo.

### Introduction

Vitiligo is a common autoimmune disease that progressively destroys melanocytes in the skin, resulting in the appearance of patchy depigmentation. This disfiguring condition frequently affects the face and other visible areas of the body, which can be psychologically devastating [1].

Vitiligo affects approximately 1% of the world's population both adults and children are affected with no predilection for sex or ethnicity. The average age at onset lies around the second to the third decade of life [2].

In recent years, vitamin D deficiency as a result of lifestyles with inadequate sun exposure, has received increased attention due to its association with the risk of serious chronic diseases. Since prolonged exposure to sunlight has been associated with risk for skin cancer, food fortification arises as an important option in obtaining vitamin D sufficiency [3].

Interleukin-21 regulates both innate and adaptive immune responses, and it not only has key roles in antitumor and antiviral responses but also exerts major effects on inflammatory responses that promote the development of autoimmune diseases and inflammatory disorders [4].

The aim of this study was to evaluate serum 25(OH)D levels, interleukin-21 serum levels and correlation between them in vitiligo patients in comparison of normal controls.

### Patients and Methods

This case control study in which 42 persons were enrolled at Dermatology Outpatient Clinics of Zagazig University Hospital during the period from March 2018 till October 2018, after the approval of the Research ethical committee of Faculty of medicine, Zagazig University and obtaining an informed consent. This study included 21 clinically diagnosed patients of vitiligo (10 males and 11 females), their ages varied from 11 to 68 years. The control group included 21 age and sex matched healthy individuals, their ages varied from 4 to 54 years.

Patients suffering from any other skin or autoimmune disorders, patients who had taken treatment for vitiligo in the last three months, pregnant and lactating women had been excluded.

All subjects underwent a complete medical examination and laboratory tests. Laboratory tests were performed within 30 days of enrollment in the study and included vitamin D and interleukin-21 levels. In all case and control groups, serum level of 25(OH)D was measured by MINI VIDAS machine which is a compact automated immunoassay system based on the Enzyme Linked Fluorescent Assay (ELFA) principles. Made in France. The normal range of vitamin D levels was 30-100 ng/ml. We then defined vitamin D insufficiency as vitamin D < 30 ng/ml and vitamin D deficiency as < 10 ng/ml.

The degree of depigmentation was measured by Wallace role of nines. While the vitiligo activity measured by Vitiligo Disease Activity Score (VIDA).

## Results

A total of 42 participants were enrolled in our study, 21 patients with vitiligo and 21 who served as controls. The patients group comprised 10 males and 11 females with a mean age of  $30.8 \pm 19.1$  years and mean duration of diagnosis  $9.3 \pm 6.9$  years of the 21 participants in the control group, 10 were males and 11 were females with a mean age of  $30.6 \pm 13.2$  years. The mean serum level of vitamin D were significantly decreased in the patients group as compared with the control group ( $17.3 \text{ ng/ml} \pm 5.3$  vs  $25.8 \text{ ng/ml} \pm 7.9$ ,  $P < 0.05$ ). There was non-significant correlation between vitamin D level with age, duration of vitiligo, and affected body surface area ( $P > 0.05$ ), but there was significant difference in 25(OH)D levels between different grades of VIDA.

The mean serum level of interleukin-21 were significantly increased in the patients group as compared with the control group ( $606.1 \text{ ng/L} \pm 549.1$  vs  $137.5 \text{ ng/L} \pm 182$ ). There was non-significant correlation between interleukin-21 level with age, duration of vitiligo, and affected body surface area ( $P > 0.05$ ), but there was significant difference in interleukin-21 levels between different grades of VIDA (increase disease activity associated with higher interleukin-21 level).

## Discussion

In the current case control study, the mean age of the case group was  $30.8 \pm 19.1$  ranged from (11-68) years, 52.4 % of them female, while the mean age of the control group was  $30.6 \pm 13.2$  ranged from (4-54) years, 52.4 % of them female.

Different mean of ages was found in another studies; 31.3 years and 28.11 years respectively Nunes and Esser, et al. and Nejad, et al. [5,6]. However in Bouayad, et al. studied group average age 36.7 years. These data reinforced that vitiligo is a disease that occurs at any age [7].

Our study showed there was a significant difference of serum levels of 25-(OH)D between patients (15.2 ng/ml) and their age and gender matched healthy controls (23.8 ng/ml.), ( $P = 0.006$ ). In agreement with our study, Beheshti, et al. in their cross-sectional study included 100 patients with Vitiligo found that the mean level of serum 25(OH) D was 42 nmol/L which had a significance difference with a normal level; ( $P = 0.042$ ) [8].

Also, Saleh, et al. in their case-control study on 40 vitiligo patients and 40 healthy, age, gender matched controls, found that 39 patients (97.5%) versus 5 controls (12.5%) have deficient 25(OH)D levels with significantly lower serum 25(OH)D levels in patients compared to controls. statistically highly significant lower serum 25(OH)D levels existed in patients compared to controls ( $P = 0.0001$ ) [9].

Parallel to this Shalaby and Ibrahim, in their case control study included 40 vitiligo patients and 40 age and sex matched healthy individuals, reported that, there was a strong correlation between patients with vitiligo and 25(OH)D deficiency [10].

While, Xu, et al. in their case control study on 280 chine patients with vitiligo, found non-significant difference between vitiligo patients and controls in serum 25(OH)D, therefore they do not support a role for vitamin D in vitiligo pathogenesis [11].

On the other hand, our study demonstrated that was statistically significant negative correlation between patients serum level of 25(OH)D and disease activity assessed by (VIDA), ( $p$  value = 0.003). While in a cross-sectional study conducted by Singla, et al. on 75 patients with vitiligo and 75 control, showed no significant correlation between serum 25(OH)D with VIDA, ( $P$  value = 0.518) [12].

On the contrary, Doss, et al. in their case control study included 30 vitiligo patients and 30 age, gender matched healthy control, find no relation between the level of 25(OH)D and the disease activity assessed by (VIDA) score [13].

In current study there was non-significant correlation existed between age, sex, affected body surface area, duration and family history of vitiligo with 25(OH)D level in case group. Parallel to this, Saleh, et al. found no significant correlations existed between serum 25(OH)D with age, duration of vitiligo, family history of vitiligo and affected body surface area of the case group [9].

Consistent with our results, Ustun, et al. a total of 25 patients and 41 controls were included in the cross-sectional study, showed no correlation between 25(OH)D with age, affected body surface area and duration of the disease in the patients with vitiligo [14].

Alsingla, et al. in their cross sectional study showed no significant correlation between serum 25 (OH)D with age, sex, affected body surface area and duration of disease in patients [12].

Inconsistent with our results, Doss, et al. showed that the affected body surface area was higher in patients with 25(OH) D level above 30 ng/ml compared to those with levels below 30 ng/ml, which means that the level of vitamin D could influence the extent of the disease [13].

In this study, the serum level of IL-21 in cases group was higher than controls group with highly significant value ( $P = 0.001$ ), also there was significant correlations between IL-21 level and disease activity ( $P = 0.008$ ). This result supported by Zhou, et al. who evaluated the potential role of IL-21 in the pathogenesis of NSV in 45 patients with active NSV. They showed elevated serum IL-21 levels in patients with NSV [15].

Our study showed non-significant correlation between serum level of IL-21 with affected body surface area of vitiligo in case group, these findings were in disagreement with Zhou, et al. who reported

that the affected body surface area of lesions is positively correlated with elevated IL-21 levels [15].

Also in case group of this study there was significant positive correlation between IL-21 and disease activity assessed by (VIDA), ( $p = 0.008$ ). But regarding age, sex, family history of autoimmune disease and disease duration there was no statistically significant correlation with IL-21 serum level. Finally in our study there was non-significant correlation between serum 25-(HO) D and IL-21 level in vitiligo patients.

## Conclusion

Based on the results obtained in the present study, we can conclude that vitamin D deficiency is present in vitiligo patients, suggesting that vitamin D deficiency may play a role in the pathogenesis of vitiligo. More studies with a large number of patients are needed to confirm this hypothesis.

Accordingly, screening for vitamin D deficiency seems of value in vitiligo patients. Moreover, the growing enthusiasm for vitamin D supplementation in autoimmune diseases emphasizes the need for timely and thorough testing of this hypothesis on a large sample size of vitiligo patients to assess the efficacy of oral vitamin D supplementation on controlling long-term disease activity and the possibility of prevention of disease onset in susceptible family members of vitiligo patients.

I was concluded that elevated serum IL-21 levels in patients with vitiligo suggested development and progression of vitiligo.

More studies are needed, to evaluate tissue levels of IL-21 in vitiligo patients, and inclusions of IL-21 as a prognostic value during examination of patients with vitiligo should be considered.

More studies are needed by pharmaceutical company with emphasis on therapeutic trials to determine the effect of lowering elevated IL-21 levels on the treatment of vitiligo.

## References

1. Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, et al. (2017) New discoveries in the pathogenesis and classification of vitiligo. *J Am Acad Dermatol* 77: 1-13.
2. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V (2011): Vitiligo: a comprehensive overview: part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. *J Am Acad Dermatol* 65: 473-491.
3. Moulas AN, Vaiou M (2018) Vitamin D fortification of foods and prospective health outcomes. *J Biotechnol* 285: 91-101.
4. Spolski R, Leonard WJ (2014) Interleukin-21: A double-edged sword with therapeutic potential. *Nat Rev Drug Discov* 13: 379.
5. Nunes DH, Esser LM (2011) Vitiligo epidemiological profile and the association with thyroid disease. *Anais Brasileiros de Dermatologia* 86: 241-248.
6. Nejad SB, Qadim HH, Nazeman L, Fadaei R, Goldust M (2013): Frequency of autoimmune diseases in those suffering from vitiligo in comparison with normal population. *Pak J Biol Sci* 16: 570-574.
7. Bouayad A, Benzekri L, Hamada S, Brick C, Hassam B, et al. (2013) Association of HLA alleles and haplotypes with vitiligo in Moroccan patients: A case-control study. *Arch Dermatol Res* 305: 925-932.
8. Beheshti A, Ghadami H, Barikani A, Beheshti A, Haj Manouchehri F (2014): Assessment of vitamin D plasma levels in patients with vitiligo vulgaris. *Acta Medicaliranica* 52: 601-606.
9. Saleh HM, Abdel Fattah NS, Hamza HT (2013): Evaluation of serum 25-hydroxyvitamin D levels in vitiligo patients with and without autoimmune diseases. *Photodermatol Photoimmunol Photomed* 29: 34-40.
10. Shalaby MES, Ibrahim SM, El Shorbagy MS, Ahmed RA (2017) Evaluation of serum level of 25-hydroxy vitamin D in vitiligo patients. *The Gulf Journal of Dermatology and Venerology* 24: 45-49.
11. Xu X, Fu WW, Wu WY (2012) Serum 25-hydroxyvitamin D deficiency in Chinese patients with vitiligo: a case-control study. *PloS one* 7: 52778.
12. Singla DS, Kaur T, Kaur I, Malhotra SK (2018) Estimation of Levels Of Serum Vitamin D3 In Vitiligo. *International Journal of Scientific Research* 7.
13. Doss RW, El-Rifaie AA, Gohary YM, Rashed LA (2015): Vitamin D receptor expression in vitiligo. *Indian J Dermatol* 60: 544.
14. Ustun I, Seraslan G, Gokce C, Motor S, Can Y, et al. (2014): Investigation of vitamin D levels in patients with vitiligo vulgaris. *Acta Dermatovenerol Croat* 22: 110-110.
15. Zhou L, Shi YL, Li K, Hamzavi I, Gao TW, et al. (2015) Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development. *Pigment Cell Melanoma Res* 28: 324-329.



Journal of Anesthesia & Clinical Care  
Journal of Addiction & Addictive Disorders  
Advances in Microbiology Research  
Advances in Industrial Biotechnology  
Journal of Agronomy & Agricultural Science  
Journal of AIDS Clinical Research & STDs  
Journal of Alcoholism, Drug Abuse & Substance Dependence  
Journal of Allergy Disorders & Therapy  
Journal of Alternative, Complementary & Integrative Medicine  
Journal of Alzheimer's & Neurodegenerative Diseases  
Journal of Angiology & Vascular Surgery  
Journal of Animal Research & Veterinary Science  
Archives of Zoological Studies  
Archives of Urology  
Journal of Atmospheric & Earth-Sciences  
Journal of Aquaculture & Fisheries  
Journal of Biotech Research & Biochemistry  
Journal of Brain & Neuroscience Research  
Journal of Cancer Biology & Treatment  
Journal of Cardiology: Study & Research  
Journal of Cell Biology & Cell Metabolism  
Journal of Clinical Dermatology & Therapy  
Journal of Clinical Immunology & Immunotherapy  
Journal of Clinical Studies & Medical Case Reports  
Journal of Community Medicine & Public Health Care  
Current Trends: Medical & Biological Engineering  
Journal of Cytology & Tissue Biology  
Journal of Dentistry: Oral Health & Cosmesis  
Journal of Diabetes & Metabolic Disorders  
Journal of Dairy Research & Technology  
Journal of Emergency Medicine Trauma & Surgical Care  
Journal of Environmental Science: Current Research  
Journal of Food Science & Nutrition  
Journal of Forensic, Legal & Investigative Sciences  
Journal of Gastroenterology & Hepatology Research  
Journal of Gerontology & Geriatric Medicine  
Journal of Genetics & Genomic Sciences  
Journal of Hematology, Blood Transfusion & Disorders  
Journal of Human Endocrinology  
Journal of Hospice & Palliative Medical Care  
Journal of Internal Medicine & Primary Healthcare  
Journal of Infectious & Non Infectious Diseases  
Journal of Light & Laser: Current Trends  
Journal of Modern Chemical Sciences  
Journal of Medicine: Study & Research  
Journal of Nanotechnology: Nanomedicine & Nanobiotechnology  
Journal of Neonatology & Clinical Pediatrics  
Journal of Nephrology & Renal Therapy  
Journal of Non Invasive Vascular Investigation  
Journal of Nuclear Medicine, Radiology & Radiation Therapy  
Journal of Obesity & Weight Loss  
Journal of Orthopedic Research & Physiotherapy  
Journal of Otolaryngology, Head & Neck Surgery  
Journal of Protein Research & Bioinformatics  
Journal of Pathology Clinical & Medical Research  
Journal of Pharmacology, Pharmaceutics & Pharmacovigilance  
Journal of Physical Medicine, Rehabilitation & Disabilities  
Journal of Plant Science: Current Research  
Journal of Psychiatry, Depression & Anxiety  
Journal of Pulmonary Medicine & Respiratory Research  
Journal of Practical & Professional Nursing  
Journal of Reproductive Medicine, Gynaecology & Obstetrics  
Journal of Stem Cells Research, Development & Therapy  
Journal of Surgery: Current Trends & Innovations  
Journal of Toxicology: Current Research  
Journal of Translational Science and Research  
Trends in Anatomy & Physiology  
Journal of Vaccines Research & Vaccination  
Journal of Virology & Antivirals  
Archives of Surgery and Surgical Education  
Sports Medicine and Injury Care Journal  
International Journal of Case Reports and Therapeutic Studies  
Journal of Ecology Research and Conservation Biology

Submit Your Manuscript: <http://www.heraldopenaccess.us/Online-Submission.php>